RU2131248C1 - Средство для ингибирования глюкозо-6-фосфатазной системы печени млекопитающих - Google Patents

Средство для ингибирования глюкозо-6-фосфатазной системы печени млекопитающих Download PDF

Info

Publication number
RU2131248C1
RU2131248C1 RU93045145A RU93045145A RU2131248C1 RU 2131248 C1 RU2131248 C1 RU 2131248C1 RU 93045145 A RU93045145 A RU 93045145A RU 93045145 A RU93045145 A RU 93045145A RU 2131248 C1 RU2131248 C1 RU 2131248C1
Authority
RU
Russia
Prior art keywords
compound
alkyl
solution
glucose
phenyl
Prior art date
Application number
RU93045145A
Other languages
English (en)
Russian (ru)
Other versions
RU93045145A (ru
Inventor
Хеммерле Хорст
Шиндлер Петер
Утц Роланд
Риппель Роберт
Херлинг Андреас
Original Assignee
Хехст АГ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Хехст АГ filed Critical Хехст АГ
Publication of RU93045145A publication Critical patent/RU93045145A/ru
Application granted granted Critical
Publication of RU2131248C1 publication Critical patent/RU2131248C1/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/56—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups bound to carbon atoms of six-membered aromatic rings and carboxyl groups bound to acyclic carbon atoms of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/36—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/013—Esters of alcohols having the esterified hydroxy group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/383—Cycloaliphatic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4018—Esters of cycloaliphatic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Transceivers (AREA)
  • Mobile Radio Communication Systems (AREA)
  • Steroid Compounds (AREA)
RU93045145A 1992-09-09 1993-09-08 Средство для ингибирования глюкозо-6-фосфатазной системы печени млекопитающих RU2131248C1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4230156.4 1992-09-09
DE4230156 1992-09-09

Publications (2)

Publication Number Publication Date
RU93045145A RU93045145A (ru) 1996-06-20
RU2131248C1 true RU2131248C1 (ru) 1999-06-10

Family

ID=6467599

Family Applications (1)

Application Number Title Priority Date Filing Date
RU93045145A RU2131248C1 (ru) 1992-09-09 1993-09-08 Средство для ингибирования глюкозо-6-фосфатазной системы печени млекопитающих

Country Status (22)

Country Link
US (1) US5451573A (https=)
EP (1) EP0587087B1 (https=)
JP (1) JPH06211737A (https=)
KR (1) KR100299205B1 (https=)
CN (1) CN1042329C (https=)
AT (1) ATE181237T1 (https=)
AU (1) AU662836B2 (https=)
CA (1) CA2105707A1 (https=)
CZ (1) CZ284995B6 (https=)
DE (1) DE59309649D1 (https=)
DK (1) DK0587087T3 (https=)
ES (1) ES2135429T3 (https=)
FI (1) FI933902L (https=)
GR (1) GR3030953T3 (https=)
HU (1) HUT64843A (https=)
IL (1) IL106935A (https=)
NO (1) NO179671C (https=)
PH (1) PH30278A (https=)
PL (1) PL300328A1 (https=)
RU (1) RU2131248C1 (https=)
TW (1) TW255880B (https=)
ZA (1) ZA936610B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2252211C2 (ru) * 1999-10-25 2005-05-20 Авентис Фарма Дойчланд Гмбх Ароматические дикетопроизводные, способы получения и применение данных соединений в качестве фармацевтических средств
RU2291858C2 (ru) * 2001-05-25 2007-01-20 Санофи-Авентис Дойчланд Гмбх Замещенные амидом карбоновой кислоты производные фенилмочевины и их применение в качестве лекарственных средств

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4404848A1 (de) * 1994-02-16 1995-08-17 Hoechst Ag Substituierte Cyclohexanolester, ihre Verwendung zur Behandlung von Krankheiten und pharmazeutische Präparate
DE4408082A1 (de) * 1994-03-10 1995-09-14 Hoechst Ag Substituierte Propan-Derivate, Verfahren zu ihrer Herstellung und die Anwendung der Verbindungen zur Behandlung von Krankheiten
DE4416433A1 (de) * 1994-05-10 1995-11-16 Hoechst Ag Cyclohexan-Derivate, Verfahren zu ihrer Herstellung und die Verwendung der Verbindungen zur Behandlung von Krankheiten
AR012449A1 (es) * 1997-04-18 2000-10-18 Hoechst Marion Roussell Deutschland Gmbh Kodaistatinas a, b, c y d, proceso para su produccion, y su uso.
JP4810558B2 (ja) * 1997-08-08 2011-11-09 江崎グリコ株式会社 リン酸化糖およびその製造方法
DE19740080A1 (de) * 1997-09-12 1999-03-18 Hoechst Marion Roussel De Gmbh Neue Phthalaldehyd-Derivate, Verfahren zu deren Herstellung und deren Verwendung
RU2221870C2 (ru) * 1998-06-24 2004-01-20 Авентис Фарма Дойчланд Гмбх Мумбайстатин, способ его получения и его применение в качестве фармацевтического препарата
EP2522663B1 (en) 2004-06-03 2015-04-01 Eisai R&D Management Co., Ltd. Intermediates for the preparation of halichondrin B
ZA200700755B (en) * 2004-07-26 2009-05-27 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes
RU2489437C2 (ru) 2007-10-03 2013-08-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Промежуточные соединения и способы синтеза аналогов галихондрина в
CN105801599A (zh) 2008-04-04 2016-07-27 卫材R&D管理有限公司 软海绵素b类似物
US20100112098A1 (en) * 2008-10-31 2010-05-06 Naturex, S.A. Effects of a decaffeinated green coffee extract on body weight control by regulation of glucose metabolism
WO2011094339A1 (en) 2010-01-26 2011-08-04 Eisai R&D Management Co., Ltd. Furo [3, 2 -b] pyrane derivatives useful in the synthesis of halichondrin b analogs
EP3689881B1 (en) 2013-11-04 2022-01-12 Eisai R&D Management Co., Ltd. Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin b
MX384292B (es) 2013-12-06 2025-03-14 Eisai R&D Man Co Ltd Metodos utiles en la sintesis de analogos de halicondrina b.
KR102743950B1 (ko) 2015-05-07 2024-12-18 에자이 알앤드디 매니지먼트 가부시키가이샤 할리콘드린 마크롤라이드의 합성에 유용한 마크로고리화 반응 및 중간체 및 기타 단편
EP3413887B1 (en) 2016-02-12 2021-04-07 Eisai R&D Management Co., Ltd. Intermediates in the synthesis of eribulin and related methods of synthesis
US11136335B2 (en) 2016-06-30 2021-10-05 Eisai R&D Management Co., Ltd. Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof
SG11202005548WA (en) 2018-01-03 2020-07-29 Eisai R&D Man Co Ltd Prins reaction and compounds useful in the synthesis of halichondrin macrolides and analogs thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60192555A (ja) * 1984-03-13 1985-10-01 Osaka Chem Lab 抗アレルギ−食品
JPS60243016A (ja) * 1984-05-17 1985-12-03 Tsumura Juntendo Inc 抗インフルエンザウイルス剤
EP0163270A3 (en) * 1984-05-23 1989-05-17 Green Cross Corporation A lipoxygenase inhibitor
DE3603576A1 (de) * 1986-02-06 1987-08-13 Code Kaffee Handel Verwendung von gerbstoffen und/oder chlorogensaeure sowie nahrungs-, genuss- und/oder arzneimittel mit gerbstoff- und/oder chlorogensaeurezusatz

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
The Merck Index, Rahway, N.Y., 1989, p. 330 - 331, abstract N 2142. Haslam E. et al. The Shikimate Pathway. Part II. Conformational Analysis of (-)-Qunic Acid and Its Derivatives by proton Magnetic Resonance spectroscopy. Journal of The Chemical society. C(Organic), 1971, N 8, p. 1496 - 1500. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2252211C2 (ru) * 1999-10-25 2005-05-20 Авентис Фарма Дойчланд Гмбх Ароматические дикетопроизводные, способы получения и применение данных соединений в качестве фармацевтических средств
RU2291858C2 (ru) * 2001-05-25 2007-01-20 Санофи-Авентис Дойчланд Гмбх Замещенные амидом карбоновой кислоты производные фенилмочевины и их применение в качестве лекарственных средств

Also Published As

Publication number Publication date
NO933201D0 (no) 1993-09-08
HUT64843A (en) 1994-03-28
ATE181237T1 (de) 1999-07-15
CN1042329C (zh) 1999-03-03
IL106935A0 (en) 1993-12-28
GR3030953T3 (en) 1999-11-30
NO933201L (no) 1994-03-10
FI933902A7 (fi) 1994-03-10
US5451573A (en) 1995-09-19
HK1011934A1 (en) 1999-07-23
KR940006580A (ko) 1994-04-25
KR100299205B1 (ko) 2001-11-22
HU9302527D0 (en) 1993-11-29
IL106935A (en) 1997-07-13
JPH06211737A (ja) 1994-08-02
CZ284995B6 (cs) 1999-04-14
EP0587087A1 (de) 1994-03-16
DE59309649D1 (de) 1999-07-22
NO179671C (no) 1996-11-27
DK0587087T3 (da) 1999-12-06
CN1086806A (zh) 1994-05-18
PH30278A (en) 1997-02-20
CA2105707A1 (en) 1994-03-10
FI933902L (fi) 1994-03-10
FI933902A0 (fi) 1993-09-07
PL300328A1 (en) 1994-03-21
EP0587087B1 (de) 1999-06-16
ZA936610B (en) 1994-03-28
AU662836B2 (en) 1995-09-14
TW255880B (https=) 1995-09-01
CZ186793A3 (en) 1994-03-16
AU4617093A (en) 1994-03-17
NO179671B (no) 1996-08-19
ES2135429T3 (es) 1999-11-01

Similar Documents

Publication Publication Date Title
RU2131248C1 (ru) Средство для ингибирования глюкозо-6-фосфатазной системы печени млекопитающих
US4686237A (en) Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
AU594064B2 (en) Imidazole analogs of mevalonolactone and derivatives thereof
RU2126378C1 (ru) Замещенные производные циклогексана
DE69327796T2 (de) Antiproliferative substituierte 5-thiapyrimidinon- und 5-selenopyrimidinonverbindungen
JPH0347167A (ja) メバロノラクトンの複素環同族体
EP0117228B1 (en) Analogs of mevalonolactone and derivatives thereof, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals
US4992462A (en) Substituted pyrroles
US4732901A (en) Certain pyridyl, thienyl or furyl propenoic acids or esters having anti-inflammatory anti-allergic properties
US4647574A (en) Hypoglycemic hydantoin derivatives
AU3368099A (en) Antidiabetic agents
US4829081A (en) Analogs of mevalonolactone and derivatives thereof
PL133220B1 (en) Method of obtaining new derivatives of oxazolidinodiene-2,4
US4588715A (en) Heptenoic acid derivatives
US4927851A (en) Analogs of mevalonolactone and derivatives thereof
EP0194226B1 (en) A pharmaceutical composition containing an imidazolidinetrione derivative or pharmaceutically acceptable salt thereof
US4804679A (en) Erythro-(E)-7-(3'-C1-3alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl)-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
US4289707A (en) Nitrogen heterocycles
PT87927B (pt) Processo para a preparacao de acidos 3,5-dihidroxi-hepta-6-enoicos substituidos por 7-(1h-pirrol-3-ilo), das suas correspondentes delta-lactonas e sais, e de composicoes farmaceuticas que os contem
US5075327A (en) Antipsoriatic agents
US4900829A (en) 2,4-disubstituted-5-cyano-1,6-dihydro-6-oxo-1-pyrimidineacetic acid aldose reductase inhibitors
US4378369A (en) Esters of 2,5-anhydro-D-mannitol
NL8003628A (nl) Acylaminobenzoeezuurderivaten, farmaceutische preparaten alsmede werkwijze voor het bereiden daarvan.
EP0410379B1 (en) Pharmaceutically active 3-aryl and 3-heteroaryl-2-fluoro-1-olefins
HK1011934B (en) Substituted cyclohexane derivatives for the treatment of diseases